We’re in the midst of earnings season, stuck in the shadow of a market that seems content to simply spin its wheels. At the same time, we’re standing against the backdrop of Einhorn’s theory that technology stocks are in a bubble, plagued by ongoing tensions in Ukraine.
Best Paper Stocks To Own Right Now: Amdocs Limited (DOX)
Amdocs Limited, together with its subsidiaries, provides software and services for communications, media, and entertainment industry service providers worldwide. It offers revenue management products, including convergent charging and billing, mediation, partner management, service delivery, compact convergence, and machine-to-machine solutions that manage the end-to-end network services revenue stream from offer definition to cash-in-hand and spans the consumer, business, and partner domains. The company also provides customer management products comprising multichannel selling, multichannel care, and proactive insight products that enable service providers to simplify the customer experience in all interaction channels and touch points; operations support systems, such as network planning, service fulfillment, service assurance, inventory and discovery, business service capture, network navigator, and radio parameter manager for fixed line, wireless, and cable networks; and network control products consisting of service controllers, home subscriber servers, policy controllers, data and Wi-Fi experience solutions, and intelligent diameter routing agents. In addition, it offers digital services, which include connected home solutions, mobile payments, digital commerce solutions, personalization, and unified communications and foundation. Further, the company provides advertising and media solutions that comprise sales experience, business agility, small-medium business experience, and business content and advertising syndication solutions. Additionally, it offers business consulting, system integration, information technology outsourcing and value process operation managed services, managed transformation, and product support services. Amdocs Limited was founded in 1988 and is based in St. Peter Port, Channel Islands.
Advisors' Opinion:- [By Omar Venerio]
The company has a current ROE of 19.09%, which is higher than the industry median and the ones exhibited by CGI Group (GIB) and Amdocs (DOX). In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. So for investors looking those levels or more, Teradata (TDC) could be the option. For more attractive ROE, Gartner (IT) and Igate (IGTE) have extremely good ratios. It is very important to understand this metric before investing and it is important to look at the trend in ROE over time.
- [By Ben Levisohn]
Shares of Iron Mountain have fallen 2.3% to $25.72 today, while comparable have been mixed. Leidos Holdings (LDOS) has ticked up 0.6% to $46.28 and Amdocs (DOX) has risen 0.8% to $37.20. Maximus (MMS), on the other hand, has fallen 1.2% to $46.22 and Xerox (XRX) is off 0.3% to $10.62.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Amdocs (NYSE: DOX ) , whose recent revenue and earnings are plotted below.
5 Best Tech Stocks For 2015: Horizon Pharma Inc (HZNP)
Horizon Pharma, Inc. (Horizon), incorporated on March 23, 2010, is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company�� other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company�� distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation. On April 1, 2010, Horizon effected a recapitalization and acquisition pursuant to which Horizon Pharma, Inc. became a holding company, that operates through its wholly owned subsidiaries, Horizon Pharma USA, Inc. (formerly Horizon Therapeutics, Inc.) and Horizon Pharma AG (formerly Nitec Pharma AG (Nitec)).
DUEXIS
DUEXIS is a combination of 800 milligram ibuprofen and 26.6 milligram famotidine in a single pill and is indicated for the relief of signs and symptoms of rheumatoid arthritis (RA), and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal (GI), ulcers in patients who are taking ibuprofen for those indications. The Company has completed two Phase III clinical trials in a total of over 1,500 patients with mild to moderate pain or arthritis that demonstrated a significant reduction in the incidence of non-steroidal anti-inflammatory drugs (NSAID)-induced upper GI ulcers when treated with DUEXIS versus ibuprofen alone.
LODOTRA
LODOTRA is a programmed release formulation of low-dose prednisone, a well-established drug use! d to inhibit the production of various pro-inflammatory cytokines, which are proteins associated with joint inflammation in RA. LODOTRA has received regulatory approval in Europe for the treatment of moderate to severe, active RA in adults when accompanied by morning stiffness. As of December 31, 2010, the Company had completed two pivotal Phase III clinical trials of LODOTRA in a total of over 600 patients with RA. The first pivotal Phase III trial supported the approval of LODOTRA in Europe in March 2009, where it is approved for marketing in 14 European countries. LODOTRA achieved significant results and met the primary endpoint in each of the two pivotal Phase III clinical trials. Its LODOTRA product was developed and is owned by Horizon Pharma AG. As of December 31, 2010, the Company markets LODOTRA in Europe through three separate agreements. Pursuant to two separate agreements, it granted Merck Serono GmbH and Merck GesmbH, an affiliate of Merck Serono, the rights to distribute and market LODOTRA in each of Germany and Austria, respectively, and pursuant to the third agreement, it granted Mundipharma rights to distribute and market LODOTRA in the rest of Europe. The Company also has a manufacturing and supply agreement with Jagotec AG under which Jagotec or its affiliates manufacture and supply LODOTRA to the Company as bulk tablets.
The Company competes with Pfizer Inc., Pozen Inc., Abbott Laboratories and Amgen Inc.
Advisors' Opinion:- [By Lisa Levin]
Horizon Pharma (NASDAQ: HZNP) shares gained 24.15% to $18.23 after the company announced its plans to acquire privately held Vidara Therapeutics International for around $660 million.
- [By Jayson Derrick]
Analysts at Piper Jaffray downgraded Horizon Pharma (NASDAQ: HZNP) to Neutral from Overweight with a price target lowered to $9 from a previous $22. Shares lost 9.67 percent, closing at $8.27.
5 Best Tech Stocks For 2015: DiaMedica Inc (DMA)
DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:- [By Richard Rhodes]
Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.
The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.
The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.
The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.
Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.
A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.
5 Best Tech Stocks For 2015: Pactera Technology International Ltd (PACT)
Pactera Technology International Ltd. (Pactera), formerly HiSoft Technology International Limited, incorporated on May 27, 2004, provides global consulting and technology services. The Company provides business/information technology (IT) consulting, solutions, and outsourcing services to a range of multinational firms through a globally integrated network of onsite and offsite delivery locations in China, the United States, Europe, Australia, Japan, Singapore and Malaysia. In January 2014, Pactera Technology International Ltd announced the acquisition of Innoveo Solutions AG.
The Company�� services include business and technology advisory, enterprise application services, business intelligence, application development and maintenance, mobility, cloud computing, infrastructure management, software product engineering and globalization, and business process outsourcing. The Company�� clients include 3M, ABB, Cathay Pacific, China Merchants Bank, Citibank, EMC, Expedia, GE, HP, IBM, Lenovo, Microsoft, Mitsubishi, NEC and TIBCO.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Pactera Technology International (Nasdaq: PACT ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment